Targeting the ALCAT1 enzyme for the treatment of pressure- overload hypertrophy
Cardiovascular Research
Mitochondrial remodeling is a central feature of heart failure pathophysiology, yet effective targeted therapies remain limited. Pressure overload induced cardiac stress drives profound metabolic and structural changes, contributing to hypertrophy, dysfunction, inflammation, and fibrosis.
ALCAT1-mediated pathological cardiolipin remodeling was shown to accelerate these processes through mitochondrial injury and depletion of tetralinoleoyl cardiolipin. Genetic deletion or pharmacological inhibition of ALCAT1 with Dafaglitapin restored mitochondrial function and reduced adverse cardiac remodeling in vivo.
The full study provides further insight into mitochondrial lipid remodeling and emerging therapeutic opportunities in pressure overload induced heart failure.
